EBMT 2019 | LentiGlobin BB305 for β-Thalassemia

Christian Chabannon

In this video, Christian Chabannon, MD, PhD, of Institut Paoli-Calmettes, Marseille, France, speaks about LentiGlobin BB305 for β-Thalassemia. Prof. Chabannon was talking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Share this video  
Related videos
9:28
New double targeting approach for beta-thalassemia
Antonella Nai
7:08
BELIEVE: β-thalassemia treatment with luspatercept reduces transfusion burden
Maria Domenica Cappellini
5:33
Luspatercept reduces transfusion burden in β-thalassemia
Maria Domenica Cappellini
2:20
Collaborating to help deliver transplants for thalassemia
Khaled Ghanem
2:12
Revolutionary approaches for thalassemia
Maria Domenica Cappellini
Thalassemia
LentiGlobin BB305
EBMT 2019
Interview
More from Christian Chabannon
Basic aspects of standard transplantation
Regulatory qualification for the EBMT patient registry for CAR T-cell therapy
Key topics at the EBMT International Transplant Course 2016
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals